China Medicine Corp banner

China Medicine Corp
OTC:CHME

Watchlist Manager
China Medicine Corp Logo
China Medicine Corp
OTC:CHME
Watchlist
Price: 0.0101 USD Market Closed
Market Cap: $281.2k

Relative Value

CHME latest financial reports are more than 12 years old.
CHME doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of CHME.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CHME Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

CHME Competitors Multiples
China Medicine Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
China Medicine Corp
OTC:CHME
281.2k USD 0 -2.5 -0.3 -0.4
US
Eli Lilly and Co
NYSE:LLY
879B USD 13.5 42.6 28.7 30.7
US
Johnson & Johnson
NYSE:JNJ
573.4B USD 6.1 21.4 14.9 18.3
CH
Roche Holding AG
SIX:ROG
256.6B CHF 4.2 20 11.8 13.3
CH
Novartis AG
SIX:NOVN
233.8B CHF 5.3 21.5 13.3 17.1
UK
AstraZeneca PLC
LSE:AZN
222.9B GBP 5.1 29.3 16.2 22.9
US
Merck & Co Inc
NYSE:MRK
286.7B USD 4.4 15.7 9.7 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 103.6 -82.1 380.1 953.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.6 10.8 8 9.4
US
Pfizer Inc
NYSE:PFE
156.1B USD 2.5 20.1 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
120.2B USD 2.5 17.1 7.2 8.8
P/E Multiple
Earnings Growth PEG
CN
China Medicine Corp
OTC:CHME
Average P/E: 22.1
Negative Multiple: -2.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.6
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.4
7%
3.1
CH
Roche Holding AG
SIX:ROG
20
14%
1.4
CH
Novartis AG
SIX:NOVN
21.5
14%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.3
26%
1.1
US
Merck & Co Inc
NYSE:MRK
15.7
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -82.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
US
Pfizer Inc
NYSE:PFE
20.1
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.1
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
China Medicine Corp
OTC:CHME
Average EV/EBITDA: 49.8
Negative Multiple: -0.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.7
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.4
CH
Roche Holding AG
SIX:ROG
11.8
6%
2
CH
Novartis AG
SIX:NOVN
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
16.2
13%
1.2
US
Merck & Co Inc
NYSE:MRK
9.7
3%
3.2
IE
E
Endo International PLC
LSE:0Y5F
380.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8
1%
8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
China Medicine Corp
OTC:CHME
Average EV/EBIT: 109.6
Negative Multiple: -0.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
30.7
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.3
7%
2.6
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
CH
Novartis AG
SIX:NOVN
17.1
9%
1.9
UK
AstraZeneca PLC
LSE:AZN
22.9
21%
1.1
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
IE
E
Endo International PLC
LSE:0Y5F
953.2
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
3%
3.1
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett